Brief: Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse for the Treatment of Fibrotic Interstitial Lung Disease
01/12/2020 13:32
Dec 1 (Reuters) - Bellerophon Therapeutics Inc BLPH.O :
* BELLEROPHON THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED
IN
PHASE 3 REBUILD STUDY EVALUATING INOPULSE® FOR THE TREATMENT OF
FIBROTIC INTERSTITIAL LUNG DISEASE
* BELLEROPHON THERAPEUTICS INC - LOOK FORWARD TO SHARING
TOP-LINE
RESULTS FROM STUDY IN 2022
Source text for Eikon: ID:nGNX6q8tkG
Further company coverage: BLPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bellerophon Therapeutics
See all newsBrief: Bellerophon Therapeutics Inc On October 12, 2023, Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Bellerophon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Bellerophon Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Nucor, Copper miners
U.S. STOCKS ON THE MOVE-Hubbell, Spire Global, FibroGen